Looking at Two Types of Radiation Therapy for Prostate Cancer Treatment
NCT06205316 · RecruitingThis trial is looking at how well two types of radiation therapy work for men with prostate cancer that has come back or spread to a few other places. One type is called stereotactic body radiation therapy (SBRT), which precisely targets tumors. The other type is called hypofractionated radiation therapy, which gives higher doses of radiation over a shorter time. Researchers want to see if SBRT can be just as effective as hypofractionated therapy but with fewer side effects and a shorter treatment time.
Locations and contact
This trial is running at 6 locations in the United States. 1 of them are currently recruiting.
United States6 locations · 1 recruiting
- Mayo Clinic in ArizonaScottsdale, ArizonaRecruiting
- Mayo Clinic Health System - MankatoMankato, MinnesotaNot Yet Recruiting
- Mayo Clinic Health System in Albert LeaAlbert Lea, MinnesotaNot Yet Recruiting
- Mayo Clinic Health System-Eau Claire ClinicEau Claire, WisconsinNot Yet Recruiting
- Mayo Clinic Health System-Franciscan HealthcareLa Crosse, WisconsinNot Yet Recruiting
- Mayo Clinic in RochesterRochester, MinnesotaNot Yet Recruiting
Who can join
Men aged 18 and older with prostate adenocarcinoma who have had surgery and have certain levels of PSA. They should not have had previous pelvic radiation or certain other medical conditions. The trial team will confirm who can join.
What happens during the trial
Participants will be randomly placed into one of two groups. One group will receive SBRT, which involves treatment every other day for about two weeks. The other group will get hypofractionated radiation therapy, which involves daily treatments for about four to six weeks. Both groups may also receive hormonal therapy as needed and will have tests like blood samples and scans to monitor their health throughout the study.
The trial team
The trial is sponsored by Mayo Clinic, and the principal investigator is Dr. Carlos E. Vargas, who works at the Mayo Clinic.
Important dates
The study started on January 22, 2024, and is expected to finish by January 22, 2030. It is currently enrolling new participants.
Additional information
The trial's ID is NCT06205316. This is a Phase 3 trial, meaning it is looking at how well the treatments work and their safety. It is not regulated by the FDA. The trial hopes to include about 118 men.
Other recruiting trials for the same condition, with the eligibility rules written in plain language.
Browse similar trials →Find a top oncologist who can tell you whether a trial is a sensible option for you.
Find a doctor →The cancer centers running studies like this one, and what each is known for.
Browse hospitals →